A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole

Nature Reviews Drug Discovery

Volumn 2, Issue 2, 2003, Pages 132-139

  Olbe, Lars ^a   Carlsson, Enar ^a   Lindberg, Per ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PICOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; THIOUREA DERIVATIVE; TIMOPRAZOLE; ENZYME INHIBITOR; PROTON PUMP;

CARCINOID; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSFORMATION; ENDOCRINE TUMOR; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; NONHUMAN; PATENT; PEPTIC ULCER; PRIORITY JOURNAL; RAT; REVIEW; STOMACH ACID SECRETION; STRUCTURE ACTIVITY RELATION; THYMUS ATROPHY; THYROID DISEASE; ZOLLINGER ELLISON SYNDROME; ANIMAL; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; STEREOISOMERISM;

ANIMALS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; OMEPRAZOLE; PROTON PUMPS; STEREOISOMERISM;

EID: 0037313425     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1010     Document Type: Review

References (55)

1. Proton Pump Inhibitors (ed. L. Olbe) (Birkhäuser Verlag, Basel, Switzerland, 1999).
2. Carlsson, E., Lindberg, P. & von Unge, S. Two of a kind. Chem. Brit. 38, 42-45 (2002).
3. Malen, C. E. & Danree, B. H. New thiocarboxamides derivatives with specific gastric antisecretory properties. J. Med. Chem. 14, 244-246 (1971).
4. Sundell, G., Sjostrand, S. E. & Olbe, L. Gastric antisecretory effects of H 83/69, a benzimidazolyl-pyridyl-methyl-sulfoxide. Acta Pharm. Tox. Suppl. 4, 77 (1977).
5. Lindberg, P. et al. Omeprazole, the first proton pump inhibitor. Med. Res. Rev 110, 1-54 (1990).
6. Olbe, L. et al. Effects of a substituted henzimidazole (H 149/94) on gastric acid secretion in humans. Gastroenterology 83, 193-198 (1982).
7. Sjostrand, S. E., Ryberg, B. & Olbe, L. Stimulation and inhibition of acid secretion by the isolated guinea pig gastric mucosa. Acta Physiol. Scand. Spec. Suppl. 181-185 (1978).
8. Fellenius, E., Elander, B., Wallmark, B., Helander, H. F. & Berglindh, T. Inhibition of acid secretion in isolated gastric glands by substituted benzimidazoles. Am. J. Physiol. 243, G505-G510 (1982).
9. Fellenius, E. et al. A micromethod for the study of secretory function in isolated human oxyntic glands from gastroscopic biopsies. Clin. Sci. 64, 423-431 (1983).
10. Forte, J. G. & Lee, H. C. Gastric adenosine triphosphatases: a review of their possible role in HCI secretion. Gastroenterology 73, 921-926 (1977).
11. + transport. Gastroenterology 73, 931-940 (1977).
12. Saccomani, G., Crago, S., Mihas, A., Dailey, D. W. & Sachs, G. Tissue and cell localization of hog gastric plasma membrane by antibody techniques. Acta Physiol. Scand. (Suppl) 293-305 (1978).
13. + ATPase. Nature 290, 159-161 (1981).
14. +)-ATPase by the substituted benzimidazole, picroprazole. Biochem. Biophys. Acta 728, 31-38 (1983).
15. Larsson, H. et al. Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology 85, 900-907 (1983).
16. Lind, T., Cederberg, C., Ekenved, G., Haglund, U. & Olbe, L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 24, 270-276 (1983).
17. Bonnevie, O. et al. Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. Scand. J. Gastroenterol. 19, 882-884 (1984).
18. Lauritsen, K. et al. Effect of omeprazole and cimetidine on duodenal ulcer. A double blind comparative trial. N. Engl. J. Med. 312, 958-961 (1985).
19. Larsson, H. et al. Plasma gastrin and gastric enterochromaffine-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90, 391-399 (1986).
20. Havu, N., Mattsson, H., Ekman, L. & Carlsson, E. Enterochromaffine-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45, 189-195 (1990).
21. Mattsson, H. et al. Partial gastric corporectomy results in hypergastrinemia and development of gastric ECL-cell carcinoids in the rat. Gastroenterology 100, 311-319 (1991).
22. Burget, D. W., Chiverton, S. G. & Hunt, R. H. Is there an optimal degree of acid suppression for healing of duodenal ulcers - a model of the relationship between ulcer healing and acid suppression. Gastroenterology 99, 345-351 (1990).
23. Walan, A. et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N. Engl. J. Med. 320, 69-75 (1989).
24. Klinkenberg-Knol, E. C., Jansen, J. M., Festen, H. P., Meuwissen, S. G. & Lamers, C. B. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1, 349-351 (1987).
25. Havelund, T. et al. Omeprazole and ranitidine in treatment of reflux esophagitis - double-blind comparative trial. Br. Med. J. 296, 89-92 (1988).
26. Hetzel, D. J. et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95, 903-912 (1988).
27. Lind, T., Cederberg, C., Olausson, M. & Olbe, L. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 99, 1593-1598 (1990).
28. +-ATPase activity. J. Biol. Chem. 260, 3681-3684 (1985).
29. Lindberg, P., Nordberg, P., Alminger, T., Brandstrom, A. & Wallmark, B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J. Med. Chem. 29, 1327-1329 (1986).
30. +-adenosine triphosphatase. Biochemistry 32, 2345-2355 (1993).
31. Lindberg, P., Brandstrom, A. & Wallmark, B. Structure-activity relationships of omeprazole analogues and their mechanism of action. Trends Pharmacol. Sci. 8, 399-402 (1987).
32. Im, W. B., Blakeman, D. P. & Sachs, G. Reversal of antisecretory activity of omeprazole by sulphydyryl compounds in isolated rabbit gastric glands. Biochim. Biophys. Acta. 845, 54-59 (1985).
33. Fujisaki, H. et al. Inhibition of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem. Pharmacol. 42, 321-328 (1991).
34. +-adenosine triphosphatase α-subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 109, 1134-1141 (1995).
35. Andersson, T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors - focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokin. 31, 9-28 (1996).
36. Creutzfeldt, W. Chiral switch, a successful way to drug development: example of Esomeprazole. Z. Gastroenterol. 38, 893-897 (2000).
37. Katsuki, T. & Sharpless, K. B. The first practical method for asymmetric epoxidation. J. Am. Chem. Soc. 102, 5974-5976 (1980).
38. Kagan, H. B. & Diter, P. Asymmetric sulfoxidation - chemical and enzymatic. Organosulfur Chem. 2, 1-39 (1998).
39. Erlandsson, P., Isaksson, R., Lorentzon, P. & Lindberg, P. Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase. The effect of the enantiomers of omeprazole on gastric glands. J. Chromatogr. 532, 305-319 (1990).
40. Lindberg, P. & von Unge, S. US Patent 5,714,504 (1988).
41. Cotton, H. et al. Asymmetric synthesis of esomeprazole. Tetrahedron-Asymmetry 11, 3819-3825 (2000).
42. Andersson, T., Rohss, K., Bredberg, E. & Hassan-Alin, M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol. Ther. 15, 1563-1569 (2001).
43. Abelo, A. et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Disp. 28, 966-972 (2000).
44. Rohss, K., Wilder Smith, C. H., Claar Nilsson, C., Lundin, C. & Hasselgren, G. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 120, A419 (2001).
45. Klinkenberg-Knol, E. C. et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118, 661-669 (2000).
46. Richter, J. E. et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am. J. Gastroenterol. 96, 656-665 (2001).
47. Lind, T. et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 14, 861-867 (2000).
48. Castell, D. et al. Esomeprazole 40 mg compared with lansoprazole 30 mg in the treatment of erosive esophagitis. Am. J. Gastroenterol. 97, 575-583 (2002).
49. Kahrilas, P. J. et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol. Ther. 14, 1249-1258 (2000).
50. Vakil, N. B. et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis. A 6-month, randomized, double blind, placebo-controlled study of efficacy and safety. Aliment. Pharmacol. Ther. 15, 926-935 (2001).
51. Lauritsen, K. et al. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed erosive esophagitis (EE). Gastroenterology 122 (Suppl 1), S 1286 (2002).
52. Suerbaum, S. & Michetti, P. Helicobacter pylori infection. N. Engl. J. Med. 347, 1175-1186 (2002).
53. Laine, L. et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am. J. Gastroenterol. 95, 3393-3398 (2000).
54. B agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 50, 19-24 (2002).
55. Skelly, M. M. & Hawkey, C. J. Potential alternatives to COX 2 inhibitors. Br. Med. J. 324, 1289-1290 (2002).